Canada - English - Health Canada

juno otc inc - loperamide hydrochloride - tablet (orally disintegrating) - 2mg - loperamide hydrochloride 2mg

Ireland - English - HPRA (Health Products Regulatory Authority)

mercury pharmaceuticals ltd - diphenoxylate hydrochloride ; atropine sulfate - tablets - 2.5/0.025 milligram - diphenoxylate

New Zealand - English - Ministry for Primary Industries

gowan crop protection limited - quinoxyfen - quinoxyfen 250 g/litre - fungicide

Canada - English - Health Canada

pharmel inc - loperamide hydrochloride - tablet - 2mg - loperamide hydrochloride 2mg - antidiarrhea agents

United States - English - NLM (National Library of Medicine)

accra-pac, inc. - homosalate (unii: v06sv4m95s) (homosalate - unii:v06sv4m95s), octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51), octisalate (unii: 4x49y0596w) (octisalate - unii:4x49y0596w), octocrylene (unii: 5a68wgf6wm) (octocrylene - unii:5a68wgf6wm), oxybenzone (unii: 95oos7ve0y) (oxybenzone - unii:95oos7ve0y), avobenzone (unii: g63qqf2nox) (avobenzone - unii:g63qqf2nox) -

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - diphenoxylate hydrochloride (unii: w24od7yw48) (diphenoxylate - unii:73312p173g) - diphenoxylate hydrochloride 2.5 mg

United States - English - NLM (National Library of Medicine)

unit dose services - diphenoxylate hydrochloride (unii: w24od7yw48) (diphenoxylate - unii:73312p173g) - diphenoxylate hydrochloride 2.5 mg

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - diphenoxylate hydrochloride (unii: w24od7yw48) (diphenoxylate - unii:73312p173g), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - diphenoxylate hydrochloride 2.5 mg - lomotil is effective as adjunctive therapy in the management of diarrhea. lomotil is contraindicated in patients with - known hypersensitivity to diphenoxylate or atropine. - obstructive jaundice. - diarrhea associated with pseudomembranous enterocolitis or enterotoxin-producing bacteria. lomotil is classified as a schedule v controlled substance by federal regulation. diphenoxylate hydrochloride is chemically related to the narcotic analgesic meperidine. in doses used for the treatment of diarrhea, whether acute or chronic, diphenoxylate has not produced addiction. diphenoxylate hydrochloride is devoid of morphine-like subjective effects at therapeutic doses. at high doses it exhibits codeine-like subjective effects. the dose which produces antidiarrheal action is widely separated from the dose which causes central nervous system effects. the insolubility of diphenoxylate hydrochloride in commonly available aqueous media precludes intravenous self-administration. a dose of 100 to 300 mg/day, which i

United States - English - NLM (National Library of Medicine)

lannett company, inc. - diphenoxylate (unii: 73312p173g) (diphenoxylate - unii:73312p173g), atropine (unii: 7c0697dr9i) (atropine - unii:7c0697dr9i) - diphenoxylate 2.5 mg - diphenoxylate hcl and atropine sulfate tablets are indicated as adjunctive therapy in the management of diarrhea in patients 13 years of age and older. diphenoxylate hcl and atropine sulfate tablets are contraindicated in: - pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (cns) depression (see warnings ). pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (cns) depression (see warnings ). - patients with diarrhea associated with pseudomembranous enterocolitis (clostridium difficile ) or other enterotoxin-producing bacteria due to the risk of gastrointestinal (gi) complications, including sepsis (see warnings ). patients with diarrhea associated with pseudomembranous enterocolitis (clostridium difficile ) or other enterotoxin-producing bacteria due to the risk of gastrointestinal (gi) complications, including sepsis (see warnings ). - patients with known hypersensitivity to diphenoxylate or atropine. patients with known hypersensitivity to diphenoxylate or atropine. - patients with obstructive jaundice. patients with obstructive jaundice. controlled substance : diphenoxylate hcl and atropine sulfate tablets are classified as a schedule v controlled substance by federal regulation. diphenoxylate hydrochloride is chemically related to the narcotic analgesic meperidine. drug abuse and dependence : in doses used for the treatment of diarrhea, whether acute or chronic, diphenoxylate has not produced addiction. diphenoxylate hydrochloride is devoid of morphine-like subjective effects at therapeutic doses. at high doses it exhibits codeine-like subjective effects. the dose which produces antidiarrheal action is widely separated from the dose which causes central nervous system effects. the insolubility of diphenoxylate hydrochloride in commonly available aqueous media precludes intravenous self-administration. a dose of 100 to 300 mg/day, which is equivalent to 40 to 120 tablets, administered to humans for 40 to 70 days, produced opiate withdrawal symptoms. since addiction to diphenoxylate hydrochloride is possible at high doses, the recommended dosage should not be exceeded.

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - diphenoxylate hydrochloride (unii: w24od7yw48) (diphenoxylate - unii:73312p173g), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - diphenoxylate hydrochloride 2.5 mg - diphenoxylate hydrochloride is effective as adjunctive therapy in the management of diarrhea. diphenoxylate hydrochloride is contraindicated in patients with: - known hypersensitivity to diphenoxylate or atropine. - obstructive jaundice. - diarrhea associated with pseudomembranous enterocolitis or enterotoxin-producing bacteria. diphenoxylate hydrochloride is classified as a schedule v controlled substance by federal regulation. diphenoxylate hydrochloride is chemically related to the narcotic analgesic meperidine. in doses used for the treatment of diarrhea, whether acute or chronic, diphenoxylate has not produced addiction. diphenoxylate hydrochloride is devoid of morphine-like subjective effects at therapeutic doses. at high doses it exhibits codeine-like subjective effects. the dose which produces antidiarrheal action is widely separated from the dose which causes central nervous system effects. the insolubility of diphenoxylate hydrochloride in commonly available aqueous media precludes intravenous self-